Pharmacokinetics and pharmacodynamics of Tarlatamab, DLL3-Targeted FDA-approved Bispecific T-Cell Engager
Crossref DOI link: https://doi.org/10.32948/ajpt.2025.04.15
Published Online: 2025-09-28
Published Print: 2025-09-28
Update policy: https://doi.org/10.32948/asme.crossmark.policy
Ahmed Abdelmoaty, Ahmed Attia
Badran, Ahmed Gamal
Publication History
Received: 2025-5-5
Accepted: 2025-8-23
Published Online: 2025-9-28
